Achieve Life Sciences Reports First Quarter 2026 Results, Announces \$354 Million Financing, Leadership Changes, and Advances in Cytisinicline Development
Seattle and Vancouver, BC – May 12, 2026 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on developing cytisinicline for nicotine dependence, has released its first quarter 2026 financial results and provided significant corporate updates that may have a substantial impact on shareholder value.
Key Highlights for Investors
- Landmark Capital Raise: Achieve closed a transformative private placement of up to \$354 million, including \$180 million upfront and up to \$174 million via milestone-based warrants. The warrants can be exercised any time prior to, and up to 20 trading days following, FDA approval of cytisinicline. Leading healthcare investors participated in the financing, with proceeds allocated to fund the pivotal ORCA-V2 Phase 3 trial for e-cigarette cessation, cytisinicline commercialization, and general corporate purposes. This strengthens the company’s balance sheet and supports the upcoming commercial launch.
- Leadership Transition and Board Expansion: Dr. Andrew D. Goldberg has been appointed Chief Executive Officer and Board member. New directors Christopher Martin, Lucian Iancovici, MD (who will become Chairman), and Aaron E. Royston, MD join, bringing expertise in commercialization, company building, and governance. Notably, Tom King will step down from the Board as of June 8, 2026. Chief Commercial Officer Jaime Xinos will depart at the end of May after nearly nine years; the company is reorganizing its commercial leadership ahead of launch, with further details to come.
- U.S.-Based Manufacturing and Regulatory Update: Achieve has transitioned its commercial manufacturing to Adare Pharma Solutions, completing technology transfer and successfully manufacturing its first engineering batch. However, its prior manufacturer received an FDA “Official Action Indicated” (OAI) classification for general cGMP issues (not specific to cytisinicline). As a result, Achieve expects a Complete Response Letter (CRL) from the FDA by the June 20, 2026 Prescription Drug User Fee Act (PDUFA) date with plans to resubmit its New Drug Application (NDA) in Q4 2026, listing Adare as the new commercial supplier. U.S. commercial launch is now anticipated in the first half of 2027.
-
Scientific and Clinical Progress:
- Recent publication in Nicotine & Tobacco Research demonstrated that cytisinicline selectively interacts with the α4β2 nicotinic receptor and has minimal interaction with the 5-HT3 receptor, potentially explaining its favorable gastrointestinal tolerability and low nausea rates observed in trials.
- At the 2026 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, pooled Phase 3 data (over 1,600 participants) showed cytisinicline significantly increased continuous abstinence rates versus placebo, even in patients who had failed varenicline and bupropion (32.4% vs. 6.0%; OR 7.5).
- Late-breaking ORCA-OL post-trial survey data revealed high satisfaction: 98% of respondents would recommend cytisinicline, 88% reported fewer cravings than with prior quit attempts, and 76% reported improvement in physical health after treatment.
-
Financial Position:
- As of March 31, 2026, cash, cash equivalents, and marketable securities were \$29.3 million, excluding an estimated \$168.6 million net from the new private placement (after agent fees and expenses).
- Q1 2026 total operating expenses were \$10.5 million, with a net loss of \$10.2 million, compared to a \$12.8 million net loss in Q1 2025. Weighted average shares outstanding increased to 53.4 million from 34.7 million.
- Balance sheet at quarter end showed \$33.1 million in assets, with \$10.7 million in stockholders’ equity and \$15.0 million in short- and long-term convertible debt.
-
Regulatory and Market Potential:
- Cytisinicline is under FDA review for smoking cessation, with the original PDUFA date of June 20, 2026; a delay is expected due to the manufacturing transition.
- The U.S. market includes 25 million adults who smoke and 18 million adults who vape e-cigarettes, with no FDA-approved therapies for vaping cessation. The FDA has awarded the Commissioner’s National Priority Voucher and Breakthrough Therapy designation for e-cigarette cessation, underscoring the significant unmet need and regulatory support.
Key Issues and Shareholder Considerations
- Regulatory Delay: The anticipated Complete Response Letter (CRL) and subsequent NDA resubmission mean a delay in potential FDA approval and commercial launch of cytisinicline in the U.S. While not related to product-specific concerns, this could impact near-term share price due to revised timelines.
- Significant Capital Infusion: The \$354 million financing is a major positive, providing financial flexibility and funding for commercialization and new clinical trials, particularly for e-cigarette cessation.
- Leadership Overhaul: High-level executive and board changes position Achieve for commercialization but also introduce short-term uncertainty until the new team demonstrates execution capability.
- Strong Clinical Data: Positive Phase 3 results, especially in previously treatment-resistant populations, support the drug’s differentiation and commercial prospects.
- Large Target Markets: The lack of FDA-approved vaping cessation therapies and strong regulatory support highlight a potentially substantial market opportunity for cytisinicline.
Conclusion
Achieve Life Sciences’ Q1 2026 report delivers several key developments that are highly relevant to investors. While the regulatory delay due to manufacturing changes carries short-term risk, the company’s robust capital position, leadership enhancements, and strong clinical data reinforce its long-term value proposition. Cytisinicline’s potential as the first new FDA-approved smoking cessation therapy in over 20 years—and possibly the first for vaping—positions Achieve as a key player in a multi-billion dollar market with significant unmet needs.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own research and consult with professional advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
